These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 23204218

  • 1. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept.
    Solari N, Palmisani E, Consolaro A, Pistorio A, Viola S, Buoncompagni A, Gattorno M, Picco P, Ruperto N, Malattia C, Martini A, Ravelli A.
    J Rheumatol; 2013 Feb; 40(2):192-200. PubMed ID: 23204218
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K, Garbutt J, Toib D, Mao J, King A, White A, French A.
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [Abstract] [Full Text] [Related]

  • 3. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
    Russo RA, Katsicas MM.
    J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
    [Abstract] [Full Text] [Related]

  • 4. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 5. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V, Horneff G.
    Rheumatology (Oxford); 2011 Jan; 50(1):214-21. PubMed ID: 21148155
    [Abstract] [Full Text] [Related]

  • 6. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 8. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, DE Benedetti F.
    J Rheumatol; 2012 Jun 07; 39(6):1287-90. PubMed ID: 22589254
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May 07; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr 07; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 12. Etanercept therapy in children with juvenile rheumatoid arthritis.
    Hung JJ, Huang JL.
    J Microbiol Immunol Infect; 2005 Dec 07; 38(6):444-6. PubMed ID: 16341346
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 07; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 14. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr 07; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 15. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis.
    Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, Rossi F, Sala I, Martini A, Ravelli A.
    J Rheumatol; 2009 Mar 07; 36(3):628-34. PubMed ID: 19208600
    [Abstract] [Full Text] [Related]

  • 16. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 07; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 17. Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept.
    Otten MH, Prince FH, Twilt M, van Rossum MA, Armbrust W, Hoppenreijs EP, Kamphuis S, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Ten Cate R, van Suijlekom-Smit LW.
    J Rheumatol; 2010 Mar 07; 37(3):665-7. PubMed ID: 20080910
    [Abstract] [Full Text] [Related]

  • 18. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G.
    Rheumatology (Oxford); 2012 Aug 15; 51(8):1407-15. PubMed ID: 22447885
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun 15; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.